Key View: Growth in Israeli consumer spending will cool over 2019 and 2020 on the back of a slowdown in domestic and global economic growth. Inflation has been stable at the lower end of the target bracket, but will pick up over the coming years amid higher oil prices and strong wage growth. These wage gains propelled consumer confidence over 2018

Key View

• We at Fitch Solutions believe that the Bank of Israel will make one 25 basis point increase to the policy rate in 2019.
• Benign inflation and a moderate slowing economic activity will reduce the need for aggressive tightening.
• A more neutral US Federal Reserve will also give Israeli policy makers reason for caution as aggressive

Key View:

• We expect Israel’s construction growth to accelerate in the short term as major projects in the rail and port sectors show good progress. We are forecasting growth of 6.5% and 6.8% y-o-y in 2019 and 2020, respectively, up from 5.9% in 2018.
• In particular, we highlight the USD3.5bn Tel Aviv Light Rail Red Line, the USD2.8bn Jerusalem

The latest: Greek energy company Energean Oil & Gas announced that first steel was cut on the Karish and Tanin floating production, storage and offloading (FPSO) vessel at the COSCO yard in Zhoushan, China, on November 26, 2018. This represents a key milestone towards the delivery of the FPSO to the Karish field in late 2020, before natural gas

Key View:

• Israel is likely to hold early elections in H119, despite efforts to hold the government together.
• We at Fitch Solutions nevertheless expect elections to produce roughly the same government coalition, with Likud heading up a group of right-wing parties.
• Policy-making is likely to be severely constrained in the interim, as coalition

Key View

• Teva Pharmaceutical Industries' revenues have continued to decline, but the sharpening of its FY18 guidance highlights confidence in the firm's business position.
• North America revenues were flat against Q218 but down against Q317, and revenues in Europe and the rest of the world also struggled; however, this in part is the result of

Key View

• Teva Pharmaceutical Industries’ Q318 results delivered a mixed performance.
• The sharp decrease in North America generic sales was partially offset by increased generic revenues in Europe.
• Teva is making significant progress towards the firm's restructuring efforts as highlighted by its earnings this quarter. 

Israel-based Teva

Key View:

- Real GDP growth will accelerate modestly in Israel in 2018, continuing to outperform most developed markets.

- Strong domestic demand, underpinned by favourable labour market dynamics and accommodative policies, will support fixed investment.

- External dynamics will remain a drag on headline growth in the near term. Over the longer

Key View: Whilst existing Crohn's disease treatments are immunosuppressive, RedHill Biopharma's RHB-104 drug candidate is the first to attempt to target what the firm and others believe is the underlying cause of the disease: Mycobacterium avium subspecies paratuberculosis (MAP) infection. These Phase III results will encourage RedHill that it is

As an aid to growth, Partner's IPTV service will only be mildly successful in the short term as it comes late into a market characterised by pay-TV saturation and dwindling operator revenues. Partner will leverage three aspects of its service: superior infrastructure, a flexible platform and premium content straight to the TV, but this will be no